Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW). It has approximately seven molecules, over two NCEs and approximately five NBEs in various stages of pre-clinical and clinical development. It is focused on developing and marketing branded and generic formulations. It focuses on manufacturing products across therapeutic areas of dermatology, respiratory and oncology. Its active pharmaceuticals ingredients (API) business spans over 80 countries, including regulated markets of the United States, Europe, Japan and Canada. Its products are primarily marketed in the United States and Western Europe. It has offices in over 40 countries, and operates approximately 20 manufacturing facilities in over five countries. It operates over five research and development (R&D) centers.
Contact Information:
Address: Unit 203, Lapanday Center, 2263, Chino Roces Avenue, Makati, 1200 Metro Manila
Phone: +63 (02) 893 7493
Maria Bella Aranas, Country Manager of Glenmark Philippines, discusses the affiliates growing product portfolio in the country and their plans to further expand into different therapeutic areas. She also discusses…
The biggest pharma stories from Southeast Asia, including GSK’s new HPF manufacturing investment, license suspensions for Samco Farma and Ciubros Farma after Indonesia’s acute kidney injury crisis, Kalbe’s Aventis share…
The latest from the pharma industry in Southeast Asia, including underwhelming results from Kalbe Pharma, Indonesia’s largest pharma company; Novavax’s vaccine manufacturing plans in the Philippines; the promising future of…
Ramon Aristoza, acting President and CEO of PhilHealth, discusses the current challenges the organization is facing in terms of realizing the goal of universal healthcare for the Filipino population, their…
The election of maverick former mayor of Davao, Rodrigo Duterte to the Filipino presidency in May 2016 represented a dramatic departure from politics as usual and raised interesting questions about…
Ravinder S. Singha, the Managing Director of Firmlink Pharma, discusses the unique business model they offer to their clients, their key success factors in entering new and sometimes challenging markets,…
Jingle Garcia Diola, Executive Director at Firmlink Pharma, details the company’s value-added services and how they are positioning themselves as the business development partner of choice for large local and…
Javish Abichandani, Chief Executive Officer of AGlobal Care Inc. in the Philippines, outlines the company’s extensive product portfolio as well as their ambitions to bring more high-quality, affordable medications into…
Jose Augusto Pascual, President and CEO of PascualLab, sheds light on the company’s current footprint in the Philippines, as well as their ambitions to even further expand their manufacturing capabilities.…
Cheryl Maley, General Manager of Novartis Philippines, discusses the company’s operations in the country, their growing portfolio of products as well as their impressive focus on research and development in…
Meneleo Hernandez, Jr., President of Multicare, describes Lupin Pharma’s Multicare operations in the Philippines and how their niche business unit strategy and strategic partnerships create a sustainable business model that…
Ivan Alexi Arota, country manager of GE Healthcare Philippines, discusses the company’s extensive efforts to increase access to their innovative, affordable products throughout the country. He also expands on the…
Bakhuti Shengelia, Director Healthcare Systems of Novartis International AG, expands on Novartis’ initiatives to increase access to healthcare in emerging markets as well as the importance of transitioning towards value-based…
See our Cookie Privacy Policy Here
